Special Issue "New Therapies for Prostate Cancer"
A special issue of Cancers (ISSN 2072-6694).
Deadline for manuscript submissions: closed (31 May 2020).
Interests: biochemically recurrent prostate cancer; novel therapeutic combination therapy for prostate cancer; personalized therapy; germline mutations
Interests: localized prostate cancer; recurrent prostate cancer; castration-resistant prostate cancer; genomic-based therapies; precision oncology
The treatment landscape for prostate cancer has significantly expanded in the last few years. Recent therapeutic successes have been accomplished by exploring novel clinical settings of use for already-approved treatments, such as abiraterone and enzalutamide. In addition, novel therapies have confirmed the clinical efficacy of treatments such as apalutamide and darolutamide, with subsequent approval by the Food and Drug Administration. Other therapies are at late stages of development, as is the case of poly (ADP-ribose) polymerase inhibitors (PARPi) and prostate-specific membrane antigen (PSMA)-targeted radiopharmaceutical agents.
Advances in technology, including new imaging modalities and genomic tests, have introduced practice-changing opportunities for localized and recurrent disease. These advances will allow for intensifying treatment of patients who are at higher risk of progression and have early detection of recurrent prostate cancer, and for selecting appropriate candidates for active surveillance. Similarly, these technological advances enable researchers to explore new concepts or stages of disease by studying metastasis-directed therapy based on molecular imaging techniques or genomic-based therapies for patients with refractory disease.
Among relevant topics, we encourage the submission of papers that discuss the role of genomic testing in personalized treatment of localized prostate cancer, surrogate endpoints, and the use of molecular imaging and treatment of recurrent disease. In addition, researchers in the field are invited to contribute their recent findings on oligometastatic and low-volume prostate cancer, theranostics, and genomic-based therapies.
Dr. Channing Judith Paller
Dr. Pedro Barata
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All papers will be peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2200 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.